Identification of Helicobacter pylori and the evolution of an efficacious childhood vaccine to protect against gastritis and peptic ulcer disease
PublisherNature Publishing Group
MetadataShow full item record
AbstractEstablishment of Helicobacter pylori infection as an etiologic agent of peptic ulcer disease and other gastric pathologies marked a revolution in gastroenterology which spurred an enormous interest in gastric physiology and immunology research. The association was soon also demonstrated in children as well. Application of antimicrobial therapies have proven remarkably efficacious in eradicating H. pylori and curing pediatric patients of duodenal ulcers as well as gastritis, negating a lifetime of ineffective therapy and life-threatening disease. Countries with high H. pylori prevalence and where H. pylori associated gastric cancer remains a primary cause of death due to cancer however would benefit from childhood vaccination. Studies in rodents and humans utilizing oral vaccination with bacterial exotoxin adjuvants demonstrated potential for limiting H. pylori colonization in the stomach. Almost 25 y of vaccine research recently culminated in a phase III clinical trial of over 4,000 children aged 6-15 y old to test an oral vaccine consisting of the H. pylori urease B subunit genetically fused to the E. coli heat labile toxin. Vaccination was demonstrated to have an efficacy of over 70%. Vaccination may now serve as an effective strategy to significantly reduce H. pylori associated disease in children throughout the world.
KeywordBacterial Vaccines--therapeutic use
Gastritis--prevention & control
Helicobacter Infections--prevention & control
Peptic Ulcer--prevention & control
Stomach Neoplasms--prevention & control
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85009830041&doi=10.1038%2fpr.2016.199&partnerID=40&md5=f136a8ff033c80809758d4636e96ae44; http://hdl.handle.net/10713/10937
- The prevalence of Helicobacter pylori in Japanese children with gastritis or peptic ulcer disease.
- Authors: Kato S, Nishino Y, Ozawa K, Konno M, Maisawa S, Toyoda S, Tajiri H, Ida S, Fujisawa T, Iinuma K
- Issue date: 2004 Aug
- Exploring novel vaccines against Helicobacter pylori: protective and therapeutic immunization.
- Authors: Vyas SP, Sihorkar V
- Issue date: 1999 Aug
- Quantifying the population impact of a prophylactic Helicobacter pylori vaccine.
- Authors: Rupnow MF, Shachter RD, Owens DK, Parsonnet J
- Issue date: 2001 Dec 12
- A double mutant heat-labile toxin from Escherichia coli, LT(R192G/L211A), is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection.
- Authors: Sjökvist Ottsjö L, Flach CF, Clements J, Holmgren J, Raghavan S
- Issue date: 2013 May